DK1146906T3 - Mukosalt afgivelsessystem - Google Patents

Mukosalt afgivelsessystem

Info

Publication number
DK1146906T3
DK1146906T3 DK00901497.8T DK00901497T DK1146906T3 DK 1146906 T3 DK1146906 T3 DK 1146906T3 DK 00901497 T DK00901497 T DK 00901497T DK 1146906 T3 DK1146906 T3 DK 1146906T3
Authority
DK
Denmark
Prior art keywords
compositions
vaccines
formulations
methods
well
Prior art date
Application number
DK00901497.8T
Other languages
English (en)
Inventor
Rahbek Janne Uldal
Hans Henrik Ipsen
Original Assignee
Alk Abello As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alk Abello As filed Critical Alk Abello As
Application granted granted Critical
Publication of DK1146906T3 publication Critical patent/DK1146906T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Vending Machines For Individual Products (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00901497.8T 1999-02-05 2000-02-04 Mukosalt afgivelsessystem DK1146906T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11889699P 1999-02-05 1999-02-05
DKPA199900155 1999-02-05
PCT/DK2000/000049 WO2000045847A1 (en) 1999-02-05 2000-02-04 Novel mucosal delivery system

Publications (1)

Publication Number Publication Date
DK1146906T3 true DK1146906T3 (da) 2011-10-24

Family

ID=26063341

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00901497.8T DK1146906T3 (da) 1999-02-05 2000-02-04 Mukosalt afgivelsessystem

Country Status (10)

Country Link
EP (1) EP1146906B1 (da)
JP (1) JP2003517452A (da)
CN (1) CN1338947B (da)
AT (1) ATE515258T1 (da)
AU (1) AU771552B2 (da)
CA (1) CA2361377C (da)
DK (1) DK1146906T3 (da)
ES (1) ES2368987T3 (da)
HK (1) HK1041219B (da)
WO (1) WO2000045847A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
AU7960101A (en) * 2000-08-09 2002-02-18 Alk Abello As Parenteral vaccine formulations and uses thereof
WO2004060265A2 (en) 2003-01-07 2004-07-22 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
US20060115499A1 (en) * 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
WO2006050729A2 (en) * 2004-11-10 2006-05-18 Alk-Abellò A/S Method of preventive treatment of allergy by mucosal administration of an allergy vaccine
EP1933867A1 (en) 2005-10-04 2008-06-25 Alk-Abello A/S Solid vaccine formulation
BRPI0618241A2 (pt) * 2005-11-04 2011-08-23 Alk Abello As uso de um alérgeno para fabricação de uma formulação de vacina lìquida para prevenção ou tratamento de alergia
WO2007051476A1 (en) * 2005-11-04 2007-05-10 Alk-Abelló A/S Use of a liquid allergy vaccine formulation for oromucosal administration
WO2009142772A2 (en) * 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
CN102441162B (zh) * 2010-10-04 2018-07-24 免疫产品美国股份有限公司 结核病的治疗和预防
EP3556398A1 (en) * 2018-04-16 2019-10-23 Croda Denmark A/S Phytates for use as a biomolecules delivery or adsorption system
CN113966228A (zh) * 2019-06-11 2022-01-21 葛兰素史密斯克莱生物公司 黏膜疫苗配制剂
CN111658611B (zh) * 2020-04-13 2021-06-01 四川大学 一种基于微乳的疫苗递送系统及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3329564A (en) 1965-06-28 1967-07-04 Parke Davis & Co Antacid preparations and means of producing the same
DE2126957B2 (de) 1971-05-29 1977-07-07 Schettler, Hermann, Dr, East Lan sing, Mich (VStA) Verfahren zur herstellung von impfstoffen gegen gaensehepatitis
US4233288A (en) * 1979-03-12 1980-11-11 Cornell John A Gum emulsified liquid package for delivering and preserving liquid content in the mouth
JPS61238728A (ja) 1985-04-16 1986-10-24 Mitsui Norin Kk 茶葉抽出物と活性水酸化アルミニウムとの抗潰瘍性複合体
IL84167A (en) 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
JPH02124832A (ja) * 1988-07-08 1990-05-14 Toray Ind Inc インターヘェロンβ組成物
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
JP3132863B2 (ja) * 1991-10-24 2001-02-05 富山化学工業株式会社 徐放性口腔用軟膏
US5360792A (en) 1991-12-20 1994-11-01 Greenwich Pharmaceuticals Incorporated Anti-proliferative and anti-inflammatory compounds: 5- or 6-deoxy hexose monosaccharides having a saturated nitrogen-containing heterocycle at the 5- or 6-position bound through the nitrogen atom
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
AU6414994A (en) 1993-03-18 1994-10-11 Cytimmune Sciences, Inc. Composition and method for reducing toxicity of biologically-active factors
GB9316745D0 (en) 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
JP2001515457A (ja) * 1995-06-07 2001-09-18 アルカームズ コントロールド セラピューティックス，インコーポレイテッド 凝集安定化生理活性物質放出用装置
AU729684B2 (en) * 1996-07-26 2001-02-08 Wyeth Holdings Corporation The NucA protein of Haemophilus influenzae and the gene encoding that protein
AU753688B2 (en) * 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69822542T2 (de) * 1997-04-23 2004-08-05 Pfizer Inc. Verkapslung einer Untereinheit des Bovinen Herpes Virus Typ-1 in wässrigen Lösungsmitteln als Impfstoff.
JPH11216357A (ja) * 1998-02-03 1999-08-10 Tsutsumi Techno Planning Kk 生理活性物質用の吸着担体
JPH11286438A (ja) * 1998-03-31 1999-10-19 Shiseido Co Ltd 徐放性製剤
JPH11302184A (ja) * 1998-04-21 1999-11-02 Taisho Pharmaceut Co Ltd 点鼻用組成物
JPH11322582A (ja) * 1998-05-06 1999-11-24 Dot:Kk 経鼻吸収用鼻粘膜付着・滞留型キャリヤ

Also Published As

Publication number Publication date
CA2361377C (en) 2009-02-03
ES2368987T3 (es) 2011-11-24
CN1338947A (zh) 2002-03-06
AU771552B2 (en) 2004-03-25
JP2003517452A (ja) 2003-05-27
HK1041219A1 (en) 2002-07-05
AU2279700A (en) 2000-08-25
CN1338947B (zh) 2012-11-14
ATE515258T1 (de) 2011-07-15
WO2000045847A8 (en) 2010-12-02
HK1041219B (en) 2011-10-21
CA2361377A1 (en) 2000-08-10
WO2000045847A1 (en) 2000-08-10
EP1146906B1 (en) 2011-07-06
EP1146906A1 (en) 2001-10-24

Similar Documents

Publication Publication Date Title
ATE515258T1 (de) Mukosales verabreichungssytem
CY1106602T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
EE05633B1 (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
ATE163913T1 (de) Ungesättigte aliphatische dicarbonsäuren
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
WO2003055513A3 (en) Bacillus subtilis spores to stimulate the immune responses
GB0109297D0 (en) Vaccine
DE60236318D1 (de) Präparationen grampositiver bakterien zur behandlung von krankheiten mit immunfehlregulation
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
DE69714011D1 (de) Die erzeugung einer immunantwort gegen erwünschte determinanten
AU1813701A (en) Interleukin-1 muteins useful as vaccine adjuvants
CA2022420A1 (en) Escherichia coli vaccine
ATE399022T1 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
DK0681479T3 (da) Immunterapeutisk præparat
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
WO1997005899A3 (en) Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
WO2000045849A3 (en) Use of cationic lipids to generate anti-tumor immunity
WO2002058535A3 (en) Use of combretastatin a4 and its prodrugs as an immune enhancing therapy
DK1063981T3 (da) Anvendelse af selegilin eller desmethylselegilin til behandling af sår, brandsår og dermatologiske skader
ES2148572T3 (es) Derivados hidrosolubles de epipodofilotoxina, su procedimiento de preparacion, su utilizacion a titulo de medicamento, y su utilizacion destinada a los tratamientos anticancerosos.
DE50014268D1 (de) Zusammensetzung, enthaltend bakterielle antigene, zum vorbeugen und behandeln von allergischen erkrankungen
MY137709A (en) Method for obtaining antigenic structures of high cross reactivity and their use in formulations
AU6942896A (en) Use of muteins of wild-type cytokines as immunogens
DE60044539D1 (de) Impfstoff enthaltend lactobacilli zur behandlung von entzündungen der prostata und gutartigen prostata-hyperplasien